The diabetes prevention program

Baseline characteristics of the randomized cohort

G. A. Bray, I. W. Culbert, C. M. Champagne, L. Dawson, B. Eberhardt, F. L. Greenway, F. G. Guillory, A. A. Hebert, M. L. Jeffirs, B. M. Kennedy, J. C. Lovejoy, L. E. Melancon, L. H. Morris, J. Perault, D. H. Ryan, D. A. Sanford, K. G. Smith, L. L. Smith, J. A. St. Amant, E. Tucker & 78 others R. T. Tulley, P. C. Vicknair, D. Williamson, J. J. Zachwieja, J. A. Tobian, M. J. Matulik, B. Clarke, D. A. Collins, K. B. Czech, C. DeSandre, D. A. Ehrmann, G. Geiger, B. Harding-Clay, R. M. Hilbrich, W. L. McNabb, K. S. Polonsky, A. R. Semenske, K. A. Stepp, P. G. Watson, J. T. Mendoza, K. A. Smith, B. J. Goldstein, C. Lark, R. Liberoni, L. Murphy, C. Pepe, J. M. Spandorfer, R. B. Goldberg, P. Rowe, J. Calles, P. Casanova, R. P. Donahue, H. J. Florez, A. Giannella, V. McLymont, J. Mendez, P. O'Hara, J. Ojito, R. Prineas, S. M. Haffner, M. G. Montez, H. Miettinen, C. M. Mobley, L. A. Mykkanen, M. M. Rozek, R. F. Hamman, P. V. Nash, B. N. Calonge, J. O. Hill, S. R. Hoyer, B. T. Jortberg, M. Miller-Stone, J. G. Regensteiner, H. Seagle, S. C. Steinke, L. Testaverde, B. Van-Dorsten, E. S. Horton, K. E. Lawton, R. A. Arky, M. Bryant, J. P. Burke, E. Caballero, K. M. Callaghan, O. P. Ganda, T. Franklin, S. D. Jackson, A. M. Jacobsen, L. M. Kula, M. Kocal, M. A. Malloy, M. Nicosia, C. F. Oldmixon, J. Pan, M. Quitingon, S. Rubtchinsky, E. W. Seely, D. Schweizer

Research output: Contribution to journalArticle

201 Citations (Scopus)

Abstract

OBJECTIVE - The Diabetes Prevention Program (DPP) is a 27-center randomized clinical trial designed to evaluate the safety and efficacy of interventions that may delay or prevent development of diabetes in people at increased risk for type 2 diabetes. RESEARCH DESIGN AND METHODS - Eligibility requirements were age ≥25 years, BMI ≥24 kg/m2 (≥22 kg/m2 for Asian-Americans), and impaired glucose tolerance plus a fasting plasma glucose of 5.3-6.9 mmol/l (or ≤6.9 mmol for American Indians). Randomization of participants into the DPP over 2.7 years ended in June 1999. Baseline data for the three treatment groups - intensive lifestyle modification, standard care plus metformin, and standard care plus placebo - are presented for the 3,234 participants who have been randomized. RESULTS - Of all participants, 55% were Caucasian, 20% were African-American, 16% were Hispanic, 5% were American Indian, and 4% were Asian-American. Their average age at entry was 51 ± 10.7 years (mean ± SD), and 67.7% were women. Moreover, 16% were <40 years of age, and 20% were ≥60 years of age. Of the women, 48% were postmenopausal. Men and women had similar frequencies of history of hypercholesterolemia (37 and 33%, respectively) or hypertension (29 and 26%, respectively). On the basis of fasting lipid determinations, 54% of men and 40% of women fit National Cholesterol Education Program criteria for abnormal lipid profiles. More men than women were current or former cigarette smokers or had a history of coronary heart disease. Furthermore, 66% of men and 71% of women had a first-degree relative with diabetes. Overall, BMI averaged 34.0 ± 6.7 kg/m2 at baseline with 57% of the men and 73% of women having a BMI ≥30 kg/m2. Average fasting plasma glucose (6.0 ± 0.5 mmol/l) and HbA(1c) (5.9 ± 0.5%) in men were comparable with values in women (5.9 ± 0.4 mmol/l and 5.9 ± 0.5%, respectively). CONCLUSIONS - The DPP has successfully randomized a large cohort of participants with a wide distribution of age, obesity, and ethnic and racial backgrounds who are at high risk for developing type 2 diabetes. The study will examine the effects of interventions on the development of diabetes.

Original languageEnglish (US)
Pages (from-to)1619-1629
Number of pages11
JournalDiabetes Care
Volume23
Issue number11
StatePublished - 2000
Externally publishedYes

Fingerprint

Fasting
Asian Americans
North American Indians
Type 2 Diabetes Mellitus
Lipids
Glucose
Glucose Intolerance
Metformin
Age Distribution
Random Allocation
Hypercholesterolemia
Hispanic Americans
Tobacco Products
African Americans
Coronary Disease
Life Style
Research Design
Randomized Controlled Trials
Obesity
Cholesterol

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Bray, G. A., Culbert, I. W., Champagne, C. M., Dawson, L., Eberhardt, B., Greenway, F. L., ... Schweizer, D. (2000). The diabetes prevention program: Baseline characteristics of the randomized cohort. Diabetes Care, 23(11), 1619-1629.

The diabetes prevention program : Baseline characteristics of the randomized cohort. / Bray, G. A.; Culbert, I. W.; Champagne, C. M.; Dawson, L.; Eberhardt, B.; Greenway, F. L.; Guillory, F. G.; Hebert, A. A.; Jeffirs, M. L.; Kennedy, B. M.; Lovejoy, J. C.; Melancon, L. E.; Morris, L. H.; Perault, J.; Ryan, D. H.; Sanford, D. A.; Smith, K. G.; Smith, L. L.; St. Amant, J. A.; Tucker, E.; Tulley, R. T.; Vicknair, P. C.; Williamson, D.; Zachwieja, J. J.; Tobian, J. A.; Matulik, M. J.; Clarke, B.; Collins, D. A.; Czech, K. B.; DeSandre, C.; Ehrmann, D. A.; Geiger, G.; Harding-Clay, B.; Hilbrich, R. M.; McNabb, W. L.; Polonsky, K. S.; Semenske, A. R.; Stepp, K. A.; Watson, P. G.; Mendoza, J. T.; Smith, K. A.; Goldstein, B. J.; Lark, C.; Liberoni, R.; Murphy, L.; Pepe, C.; Spandorfer, J. M.; Goldberg, R. B.; Rowe, P.; Calles, J.; Casanova, P.; Donahue, R. P.; Florez, H. J.; Giannella, A.; McLymont, V.; Mendez, J.; O'Hara, P.; Ojito, J.; Prineas, R.; Haffner, S. M.; Montez, M. G.; Miettinen, H.; Mobley, C. M.; Mykkanen, L. A.; Rozek, M. M.; Hamman, R. F.; Nash, P. V.; Calonge, B. N.; Hill, J. O.; Hoyer, S. R.; Jortberg, B. T.; Miller-Stone, M.; Regensteiner, J. G.; Seagle, H.; Steinke, S. C.; Testaverde, L.; Van-Dorsten, B.; Horton, E. S.; Lawton, K. E.; Arky, R. A.; Bryant, M.; Burke, J. P.; Caballero, E.; Callaghan, K. M.; Ganda, O. P.; Franklin, T.; Jackson, S. D.; Jacobsen, A. M.; Kula, L. M.; Kocal, M.; Malloy, M. A.; Nicosia, M.; Oldmixon, C. F.; Pan, J.; Quitingon, M.; Rubtchinsky, S.; Seely, E. W.; Schweizer, D.

In: Diabetes Care, Vol. 23, No. 11, 2000, p. 1619-1629.

Research output: Contribution to journalArticle

Bray, GA, Culbert, IW, Champagne, CM, Dawson, L, Eberhardt, B, Greenway, FL, Guillory, FG, Hebert, AA, Jeffirs, ML, Kennedy, BM, Lovejoy, JC, Melancon, LE, Morris, LH, Perault, J, Ryan, DH, Sanford, DA, Smith, KG, Smith, LL, St. Amant, JA, Tucker, E, Tulley, RT, Vicknair, PC, Williamson, D, Zachwieja, JJ, Tobian, JA, Matulik, MJ, Clarke, B, Collins, DA, Czech, KB, DeSandre, C, Ehrmann, DA, Geiger, G, Harding-Clay, B, Hilbrich, RM, McNabb, WL, Polonsky, KS, Semenske, AR, Stepp, KA, Watson, PG, Mendoza, JT, Smith, KA, Goldstein, BJ, Lark, C, Liberoni, R, Murphy, L, Pepe, C, Spandorfer, JM, Goldberg, RB, Rowe, P, Calles, J, Casanova, P, Donahue, RP, Florez, HJ, Giannella, A, McLymont, V, Mendez, J, O'Hara, P, Ojito, J, Prineas, R, Haffner, SM, Montez, MG, Miettinen, H, Mobley, CM, Mykkanen, LA, Rozek, MM, Hamman, RF, Nash, PV, Calonge, BN, Hill, JO, Hoyer, SR, Jortberg, BT, Miller-Stone, M, Regensteiner, JG, Seagle, H, Steinke, SC, Testaverde, L, Van-Dorsten, B, Horton, ES, Lawton, KE, Arky, RA, Bryant, M, Burke, JP, Caballero, E, Callaghan, KM, Ganda, OP, Franklin, T, Jackson, SD, Jacobsen, AM, Kula, LM, Kocal, M, Malloy, MA, Nicosia, M, Oldmixon, CF, Pan, J, Quitingon, M, Rubtchinsky, S, Seely, EW & Schweizer, D 2000, 'The diabetes prevention program: Baseline characteristics of the randomized cohort', Diabetes Care, vol. 23, no. 11, pp. 1619-1629.
Bray GA, Culbert IW, Champagne CM, Dawson L, Eberhardt B, Greenway FL et al. The diabetes prevention program: Baseline characteristics of the randomized cohort. Diabetes Care. 2000;23(11):1619-1629.
Bray, G. A. ; Culbert, I. W. ; Champagne, C. M. ; Dawson, L. ; Eberhardt, B. ; Greenway, F. L. ; Guillory, F. G. ; Hebert, A. A. ; Jeffirs, M. L. ; Kennedy, B. M. ; Lovejoy, J. C. ; Melancon, L. E. ; Morris, L. H. ; Perault, J. ; Ryan, D. H. ; Sanford, D. A. ; Smith, K. G. ; Smith, L. L. ; St. Amant, J. A. ; Tucker, E. ; Tulley, R. T. ; Vicknair, P. C. ; Williamson, D. ; Zachwieja, J. J. ; Tobian, J. A. ; Matulik, M. J. ; Clarke, B. ; Collins, D. A. ; Czech, K. B. ; DeSandre, C. ; Ehrmann, D. A. ; Geiger, G. ; Harding-Clay, B. ; Hilbrich, R. M. ; McNabb, W. L. ; Polonsky, K. S. ; Semenske, A. R. ; Stepp, K. A. ; Watson, P. G. ; Mendoza, J. T. ; Smith, K. A. ; Goldstein, B. J. ; Lark, C. ; Liberoni, R. ; Murphy, L. ; Pepe, C. ; Spandorfer, J. M. ; Goldberg, R. B. ; Rowe, P. ; Calles, J. ; Casanova, P. ; Donahue, R. P. ; Florez, H. J. ; Giannella, A. ; McLymont, V. ; Mendez, J. ; O'Hara, P. ; Ojito, J. ; Prineas, R. ; Haffner, S. M. ; Montez, M. G. ; Miettinen, H. ; Mobley, C. M. ; Mykkanen, L. A. ; Rozek, M. M. ; Hamman, R. F. ; Nash, P. V. ; Calonge, B. N. ; Hill, J. O. ; Hoyer, S. R. ; Jortberg, B. T. ; Miller-Stone, M. ; Regensteiner, J. G. ; Seagle, H. ; Steinke, S. C. ; Testaverde, L. ; Van-Dorsten, B. ; Horton, E. S. ; Lawton, K. E. ; Arky, R. A. ; Bryant, M. ; Burke, J. P. ; Caballero, E. ; Callaghan, K. M. ; Ganda, O. P. ; Franklin, T. ; Jackson, S. D. ; Jacobsen, A. M. ; Kula, L. M. ; Kocal, M. ; Malloy, M. A. ; Nicosia, M. ; Oldmixon, C. F. ; Pan, J. ; Quitingon, M. ; Rubtchinsky, S. ; Seely, E. W. ; Schweizer, D. / The diabetes prevention program : Baseline characteristics of the randomized cohort. In: Diabetes Care. 2000 ; Vol. 23, No. 11. pp. 1619-1629.
@article{a19dfd69a5cc4157bbca8cbfd953c4f4,
title = "The diabetes prevention program: Baseline characteristics of the randomized cohort",
abstract = "OBJECTIVE - The Diabetes Prevention Program (DPP) is a 27-center randomized clinical trial designed to evaluate the safety and efficacy of interventions that may delay or prevent development of diabetes in people at increased risk for type 2 diabetes. RESEARCH DESIGN AND METHODS - Eligibility requirements were age ≥25 years, BMI ≥24 kg/m2 (≥22 kg/m2 for Asian-Americans), and impaired glucose tolerance plus a fasting plasma glucose of 5.3-6.9 mmol/l (or ≤6.9 mmol for American Indians). Randomization of participants into the DPP over 2.7 years ended in June 1999. Baseline data for the three treatment groups - intensive lifestyle modification, standard care plus metformin, and standard care plus placebo - are presented for the 3,234 participants who have been randomized. RESULTS - Of all participants, 55{\%} were Caucasian, 20{\%} were African-American, 16{\%} were Hispanic, 5{\%} were American Indian, and 4{\%} were Asian-American. Their average age at entry was 51 ± 10.7 years (mean ± SD), and 67.7{\%} were women. Moreover, 16{\%} were <40 years of age, and 20{\%} were ≥60 years of age. Of the women, 48{\%} were postmenopausal. Men and women had similar frequencies of history of hypercholesterolemia (37 and 33{\%}, respectively) or hypertension (29 and 26{\%}, respectively). On the basis of fasting lipid determinations, 54{\%} of men and 40{\%} of women fit National Cholesterol Education Program criteria for abnormal lipid profiles. More men than women were current or former cigarette smokers or had a history of coronary heart disease. Furthermore, 66{\%} of men and 71{\%} of women had a first-degree relative with diabetes. Overall, BMI averaged 34.0 ± 6.7 kg/m2 at baseline with 57{\%} of the men and 73{\%} of women having a BMI ≥30 kg/m2. Average fasting plasma glucose (6.0 ± 0.5 mmol/l) and HbA(1c) (5.9 ± 0.5{\%}) in men were comparable with values in women (5.9 ± 0.4 mmol/l and 5.9 ± 0.5{\%}, respectively). CONCLUSIONS - The DPP has successfully randomized a large cohort of participants with a wide distribution of age, obesity, and ethnic and racial backgrounds who are at high risk for developing type 2 diabetes. The study will examine the effects of interventions on the development of diabetes.",
author = "Bray, {G. A.} and Culbert, {I. W.} and Champagne, {C. M.} and L. Dawson and B. Eberhardt and Greenway, {F. L.} and Guillory, {F. G.} and Hebert, {A. A.} and Jeffirs, {M. L.} and Kennedy, {B. M.} and Lovejoy, {J. C.} and Melancon, {L. E.} and Morris, {L. H.} and J. Perault and Ryan, {D. H.} and Sanford, {D. A.} and Smith, {K. G.} and Smith, {L. L.} and {St. Amant}, {J. A.} and E. Tucker and Tulley, {R. T.} and Vicknair, {P. C.} and D. Williamson and Zachwieja, {J. J.} and Tobian, {J. A.} and Matulik, {M. J.} and B. Clarke and Collins, {D. A.} and Czech, {K. B.} and C. DeSandre and Ehrmann, {D. A.} and G. Geiger and B. Harding-Clay and Hilbrich, {R. M.} and McNabb, {W. L.} and Polonsky, {K. S.} and Semenske, {A. R.} and Stepp, {K. A.} and Watson, {P. G.} and Mendoza, {J. T.} and Smith, {K. A.} and Goldstein, {B. J.} and C. Lark and R. Liberoni and L. Murphy and C. Pepe and Spandorfer, {J. M.} and Goldberg, {R. B.} and P. Rowe and J. Calles and P. Casanova and Donahue, {R. P.} and Florez, {H. J.} and A. Giannella and V. McLymont and J. Mendez and P. O'Hara and J. Ojito and R. Prineas and Haffner, {S. M.} and Montez, {M. G.} and H. Miettinen and Mobley, {C. M.} and Mykkanen, {L. A.} and Rozek, {M. M.} and Hamman, {R. F.} and Nash, {P. V.} and Calonge, {B. N.} and Hill, {J. O.} and Hoyer, {S. R.} and Jortberg, {B. T.} and M. Miller-Stone and Regensteiner, {J. G.} and H. Seagle and Steinke, {S. C.} and L. Testaverde and B. Van-Dorsten and Horton, {E. S.} and Lawton, {K. E.} and Arky, {R. A.} and M. Bryant and Burke, {J. P.} and E. Caballero and Callaghan, {K. M.} and Ganda, {O. P.} and T. Franklin and Jackson, {S. D.} and Jacobsen, {A. M.} and Kula, {L. M.} and M. Kocal and Malloy, {M. A.} and M. Nicosia and Oldmixon, {C. F.} and J. Pan and M. Quitingon and S. Rubtchinsky and Seely, {E. W.} and D. Schweizer",
year = "2000",
language = "English (US)",
volume = "23",
pages = "1619--1629",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "11",

}

TY - JOUR

T1 - The diabetes prevention program

T2 - Baseline characteristics of the randomized cohort

AU - Bray, G. A.

AU - Culbert, I. W.

AU - Champagne, C. M.

AU - Dawson, L.

AU - Eberhardt, B.

AU - Greenway, F. L.

AU - Guillory, F. G.

AU - Hebert, A. A.

AU - Jeffirs, M. L.

AU - Kennedy, B. M.

AU - Lovejoy, J. C.

AU - Melancon, L. E.

AU - Morris, L. H.

AU - Perault, J.

AU - Ryan, D. H.

AU - Sanford, D. A.

AU - Smith, K. G.

AU - Smith, L. L.

AU - St. Amant, J. A.

AU - Tucker, E.

AU - Tulley, R. T.

AU - Vicknair, P. C.

AU - Williamson, D.

AU - Zachwieja, J. J.

AU - Tobian, J. A.

AU - Matulik, M. J.

AU - Clarke, B.

AU - Collins, D. A.

AU - Czech, K. B.

AU - DeSandre, C.

AU - Ehrmann, D. A.

AU - Geiger, G.

AU - Harding-Clay, B.

AU - Hilbrich, R. M.

AU - McNabb, W. L.

AU - Polonsky, K. S.

AU - Semenske, A. R.

AU - Stepp, K. A.

AU - Watson, P. G.

AU - Mendoza, J. T.

AU - Smith, K. A.

AU - Goldstein, B. J.

AU - Lark, C.

AU - Liberoni, R.

AU - Murphy, L.

AU - Pepe, C.

AU - Spandorfer, J. M.

AU - Goldberg, R. B.

AU - Rowe, P.

AU - Calles, J.

AU - Casanova, P.

AU - Donahue, R. P.

AU - Florez, H. J.

AU - Giannella, A.

AU - McLymont, V.

AU - Mendez, J.

AU - O'Hara, P.

AU - Ojito, J.

AU - Prineas, R.

AU - Haffner, S. M.

AU - Montez, M. G.

AU - Miettinen, H.

AU - Mobley, C. M.

AU - Mykkanen, L. A.

AU - Rozek, M. M.

AU - Hamman, R. F.

AU - Nash, P. V.

AU - Calonge, B. N.

AU - Hill, J. O.

AU - Hoyer, S. R.

AU - Jortberg, B. T.

AU - Miller-Stone, M.

AU - Regensteiner, J. G.

AU - Seagle, H.

AU - Steinke, S. C.

AU - Testaverde, L.

AU - Van-Dorsten, B.

AU - Horton, E. S.

AU - Lawton, K. E.

AU - Arky, R. A.

AU - Bryant, M.

AU - Burke, J. P.

AU - Caballero, E.

AU - Callaghan, K. M.

AU - Ganda, O. P.

AU - Franklin, T.

AU - Jackson, S. D.

AU - Jacobsen, A. M.

AU - Kula, L. M.

AU - Kocal, M.

AU - Malloy, M. A.

AU - Nicosia, M.

AU - Oldmixon, C. F.

AU - Pan, J.

AU - Quitingon, M.

AU - Rubtchinsky, S.

AU - Seely, E. W.

AU - Schweizer, D.

PY - 2000

Y1 - 2000

N2 - OBJECTIVE - The Diabetes Prevention Program (DPP) is a 27-center randomized clinical trial designed to evaluate the safety and efficacy of interventions that may delay or prevent development of diabetes in people at increased risk for type 2 diabetes. RESEARCH DESIGN AND METHODS - Eligibility requirements were age ≥25 years, BMI ≥24 kg/m2 (≥22 kg/m2 for Asian-Americans), and impaired glucose tolerance plus a fasting plasma glucose of 5.3-6.9 mmol/l (or ≤6.9 mmol for American Indians). Randomization of participants into the DPP over 2.7 years ended in June 1999. Baseline data for the three treatment groups - intensive lifestyle modification, standard care plus metformin, and standard care plus placebo - are presented for the 3,234 participants who have been randomized. RESULTS - Of all participants, 55% were Caucasian, 20% were African-American, 16% were Hispanic, 5% were American Indian, and 4% were Asian-American. Their average age at entry was 51 ± 10.7 years (mean ± SD), and 67.7% were women. Moreover, 16% were <40 years of age, and 20% were ≥60 years of age. Of the women, 48% were postmenopausal. Men and women had similar frequencies of history of hypercholesterolemia (37 and 33%, respectively) or hypertension (29 and 26%, respectively). On the basis of fasting lipid determinations, 54% of men and 40% of women fit National Cholesterol Education Program criteria for abnormal lipid profiles. More men than women were current or former cigarette smokers or had a history of coronary heart disease. Furthermore, 66% of men and 71% of women had a first-degree relative with diabetes. Overall, BMI averaged 34.0 ± 6.7 kg/m2 at baseline with 57% of the men and 73% of women having a BMI ≥30 kg/m2. Average fasting plasma glucose (6.0 ± 0.5 mmol/l) and HbA(1c) (5.9 ± 0.5%) in men were comparable with values in women (5.9 ± 0.4 mmol/l and 5.9 ± 0.5%, respectively). CONCLUSIONS - The DPP has successfully randomized a large cohort of participants with a wide distribution of age, obesity, and ethnic and racial backgrounds who are at high risk for developing type 2 diabetes. The study will examine the effects of interventions on the development of diabetes.

AB - OBJECTIVE - The Diabetes Prevention Program (DPP) is a 27-center randomized clinical trial designed to evaluate the safety and efficacy of interventions that may delay or prevent development of diabetes in people at increased risk for type 2 diabetes. RESEARCH DESIGN AND METHODS - Eligibility requirements were age ≥25 years, BMI ≥24 kg/m2 (≥22 kg/m2 for Asian-Americans), and impaired glucose tolerance plus a fasting plasma glucose of 5.3-6.9 mmol/l (or ≤6.9 mmol for American Indians). Randomization of participants into the DPP over 2.7 years ended in June 1999. Baseline data for the three treatment groups - intensive lifestyle modification, standard care plus metformin, and standard care plus placebo - are presented for the 3,234 participants who have been randomized. RESULTS - Of all participants, 55% were Caucasian, 20% were African-American, 16% were Hispanic, 5% were American Indian, and 4% were Asian-American. Their average age at entry was 51 ± 10.7 years (mean ± SD), and 67.7% were women. Moreover, 16% were <40 years of age, and 20% were ≥60 years of age. Of the women, 48% were postmenopausal. Men and women had similar frequencies of history of hypercholesterolemia (37 and 33%, respectively) or hypertension (29 and 26%, respectively). On the basis of fasting lipid determinations, 54% of men and 40% of women fit National Cholesterol Education Program criteria for abnormal lipid profiles. More men than women were current or former cigarette smokers or had a history of coronary heart disease. Furthermore, 66% of men and 71% of women had a first-degree relative with diabetes. Overall, BMI averaged 34.0 ± 6.7 kg/m2 at baseline with 57% of the men and 73% of women having a BMI ≥30 kg/m2. Average fasting plasma glucose (6.0 ± 0.5 mmol/l) and HbA(1c) (5.9 ± 0.5%) in men were comparable with values in women (5.9 ± 0.4 mmol/l and 5.9 ± 0.5%, respectively). CONCLUSIONS - The DPP has successfully randomized a large cohort of participants with a wide distribution of age, obesity, and ethnic and racial backgrounds who are at high risk for developing type 2 diabetes. The study will examine the effects of interventions on the development of diabetes.

UR - http://www.scopus.com/inward/record.url?scp=0033760858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033760858&partnerID=8YFLogxK

M3 - Article

VL - 23

SP - 1619

EP - 1629

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 11

ER -